A fine balance between fibrin generation and fibrin dissolution must be maintained in order to assure adequate hemostasis, while preventing thrombosis. An intricate fibrinolytic system is responsible for clot lysis. Recently, abnormalities of several components of this system resulting in thrombotic or hemorrhagic manifestations, have been identified in a small number of patients, supporting the physiological importance of the fibrinolytic system. The applicant proposes to examine individuals with idiopathic thrombosis for abnormalities of plasminogen, the key component of the fibrinolytic system. Over thirty patients with recurrent thrombosis or thrombosis occurring at a young age are now under investigation by the applicant. In addition to measurements of circulating plasminogen and plasmin inhibitor concentrationns, plasma-based chromogenic substrate assays are being utilized to assess plasminogen activation, catalytic activity of plasmin and the lysine binding capacity of plasminogen, as alterations of any of these could theoretically result in subphysiologic lysis. In preliminary studies we have identified five individuals with probable abnormalities. In patients with such findings, isolated plasminogen and/or plasminogen-depleted plasma will be examined utilizing a variety of biochemical techniques. Functional or structural defects in plasminogen will be defined. Investigations include electrophoretic studies of plasminogen, kinetics of its activation, analysis of kinetics of generated plasmin, and characterization of lysine binding by the plasminogen. The proposed studies will examine the participation of other plasma constituents in physiological fibrinolysis by identifying the basis for altered activity in those individuals where the isolated plasminogen is normal. Other groups of individuals, not overtly """"""""hypercoaguable"""""""" have been found to have alterations in fibrinolytic activity, e.g. women on combination oral contraceptives and patients in the period immediately following myocardial infarction. These two groups of patients will be studied in a similar manner to determine the basis for the variant plasminogen activity. Through these studies, the applicant hopes to clarify the role of plasminogen and associated components in the control of clot dissolution and maintenance of blood fluidity.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL032901-02
Application #
3344439
Study Section
Hematology Subcommittee 2 (HEM)
Project Start
1984-07-01
Project End
1987-06-30
Budget Start
1985-07-01
Budget End
1986-06-30
Support Year
2
Fiscal Year
1985
Total Cost
Indirect Cost
Name
University of Florida
Department
Type
Schools of Medicine
DUNS #
073130411
City
Gainesville
State
FL
Country
United States
Zip Code
32611
Grant, M B; Fitzgerald, C; Guay, C et al. (1989) Fibrinolytic capacity following stimulation with desmopressin acetate in patients with diabetes mellitus. Metabolism 38:901-7
Grant, M B; Guay, C; Lottenberg, R (1988) Desmopressin stimulates parallel norepinephrine and tissue plasminogen activator release in normal subjects and patients with diabetes mellitus. Thromb Haemost 59:269-72
Broeseker, T A; Boyle, M D; Lottenberg, R (1988) Characterization of the interaction of human plasmin with its specific receptor on a group A streptococcus. Microb Pathog 5:19-27
Hach-Wunderle, V; Scharrer, I; Lottenberg, R (1988) Congenital deficiency of plasminogen and its relationship to venous thrombosis. Thromb Haemost 59:277-80
Lottenberg, R; Sjak-Shie, N; Fazleabas, A T et al. (1988) Aprotinin inhibits urokinase but not tissue-type plasminogen activator. Thromb Res 49:549-56
Lottenberg, R; Broder, C C; Boyle, M D (1987) Identification of a specific receptor for plasmin on a group A streptococcus. Infect Immun 55:1914-8
Lottenberg, R; Willis, D C (1986) The rapid inhibition of urokinase by plasma from pregnant women at risk for abruptio placenta. Thromb Res 44:807-15